UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Its Charter)
(State of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(
(Registrant's telephone number, including area code)
Not
Applicable
(Former name, former address and former fiscal year, if changed
since last report date)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act: | ||
Title of each class | Ticker symbol(s) | Name of each exchange on which registered |
The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01 Regulation FD Disclosure.
On July 20, 2022, the Company issued a press release announcing it has entered into an agreement with Fisher Healthcare, a part of Thermo Fisher Scientific to distribute its proprietary HemeScreen assays to its customers.
The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
99.1 | Precipio Inc Press Release, dated July 20, 2022 |
104 | Cover Page Interactive Data File (cover page XBRL tags are embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PRECIPIO, INC. | ||
By: | s/ Ilan Danieli | |
Name: | Ilan Danieli | |
Title: | Chief Executive Officer |
Date: July 20, 2022
Exhibit 99.1
Precipio to distribute HemeScreen® through Fisher Healthcare channel
Agreement Enhances Precipio’s Product Reach to US Laboratories
NEW HAVEN, CT – (Globe Newswire) – (July 20th, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced that it has entered into an agreement with Fisher Healthcare, a part of Thermo Fisher Scientific to distribute its proprietary HemeScreen assays to its customers.
As one of the largest distributors of laboratory and diagnostic products nationwide, the Fisher Healthcare channel will enable Precipio to expand access to laboratories across the United States for Precipio’s HemeScreen suite of products. This partnership is a logical expansion of Precipio’s distribution strategy, the leveraging of industry leading sales channels rather than building its own sales force.
“Entering into an agreement with the Fisher Healthcare channel will expand access to customers and drive distribution and revenue for our HemeScreen product suite”, said Keith Meadors, Precipio’s Senior Vice President of Products. “Now more than ever, it is important for laboratories to have products that are accurate, decrease turnaround times and are cost-effective. The HemeScreen technology excels in these areas and will support the Fisher Healthcare channel in its commitment to serve its customers.”
About Precipio
Precipio has built a robust specialty cancer diagnostics platform that enables the rapid development of highly differentiated, proprietary clinical diagnostics products which provide superior clinical, operational, and economic benefits to laboratories worldwide. Precipio leverages its relationships with world-class academic institutions, coupled with its in-house clinical laboratory which enables its internal product development and testing engine to create and offer proprietary tests and reagents that enhance diagnostic accuracy, and improve patient care. For more information, please visit www.precipiodx.com.
Please follow us on LinkedIn, on Twitter @PrecipioDx and on Facebook.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, statements related to the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses of the government, consumers, and the company, on our business, financial condition and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management’s expectations, or could affect the company’s ability to achieve its strategic goals, include the uncertainties relating to the impact of COVID-19 on the company’s business, operations and employees and the other factors that are described in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis” in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as updated from time to time in the company’s Securities and Exchange Commission filings.
The company’s forward-looking statements in this press release are based on management’s current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this release. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws.
Inquiries:
investors@precipiodx.com
+1-203-787-7888 Ext. 523
H:AJ?Q1FBTO3;*Y
MLO#HD#W5Y.NUI@#G:H_SVSC'/IT<<5G:I&@"0PH%4#HJ@?X5* , 8%17/-K
M-_N-_*E*5]%L%CBV^+OA!21]LG..XMGY_2D_X6]X0_Y_+C_P&?\ PJO\(K:"
M7P'$TD,;M]IEY903]ZN[^Q6O_/M#_P!^Q5RY(MJPE=G%M\7_ B%)6YNG/95
MMFR?SK,MXM5^(_B&QU"\L);#PYI\GG0Q3C#W+CH2/3],9'.:W/'&J77A>'3M
M5L[*VDT^.X"WZ^4"X0\ J>V#^N*ZZ">*ZMX[B!P\4JAT=>C*1D&BZBKQ0;[F
M!X__ .1!UO\ Z]6K*TWQ5I?A7P#X=FU1Y42>UC1/+C+Y(0'MTK5\?_\ (@ZW
M_P!>K5)X-1)/ ^B!U5A]CBX(S_"*2MR:]_T'U,+_ (6_X2_Y[W?_ (#-3D^+
MOA-W5!/=Y8@#_1F[UVOV:#_GC'_WR*46\ ((AC!'^R*5X=OQ#4D!R,U%
Cover |
Jul. 20, 2022 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jul. 20, 2022 |
Entity File Number | 001-36439 |
Entity Registrant Name | PRECIPIO, INC. |
Entity Central Index Key | 0001043961 |
Entity Tax Identification Number | 91-1789357 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 4 Science Park |
Entity Address, City or Town | New Haven |
Entity Address, State or Province | CT |
Entity Address, Postal Zip Code | 06511 |
City Area Code | 203 |
Local Phone Number | 787-7888 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.01 par value per share |
Trading Symbol | PRPO |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
RHY_U=3_ 102P,$% @ %9KT5)>*NQS M$P( L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/: (7->=I3W;+T]!;X"O.DQQ M0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'B4?'D7 M8FYJD6:>IK&HP=MX1PT$G53$WHI"/J:Q8;!EK '$NW2:9;/46PQFN1BUMIS> M A(H!"DHV1%[A$O\G7 D(GP&LK\,S4-AB.G8RF2&]B]#V,YU#BG/]3(U45%K"FHO409.B1P74&0ZRQ MB28)UD-N5G0&[O+H YMRR"9JZJ8IGJ,.>%,.]D9/)508H'Q3F:B\]E-L.>F. M7F=Z_S!YU!Y:YU;*O8=7LN48Y0]02P,$% @ %9KT5"0>FZ*M M^ $ !H !X;"]? +7_OR4Z?:!1W;J"V\R1& M:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T M==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+) M(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0 ( !6:]%1ED'F2 M&0$ ,\# 3 6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N M+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78 ME!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')O MJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1< M^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!G MZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%. M6X.^D X K @ $0 M @ &O 9&]C4')O<',O8V]R92YX;6Q02P$"% ,4 " 5 MFO14F5R<(Q & "<)P $P @ ', 0 >&PO=&AE;64O=&AE M;64Q+GAM;%!+ 0(4 Q0 ( !6:]%0KV?S*0P0 '$0 8 M " @0T( !X;"]W;W)K &PO &PO7W)E;',O=V]R:V)O M;VLN>&UL+G)E;'-02P$"% ,4 " 5FO1499!YDAD! #/ P $P M @ &0$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" ( #:$P ! end
'DP$YF6: DYVS;G A>C,;T0");XS!>=(^,"/Y"'B'C(=$UYX-;3'=!AYA3D4.TIN
M6BL3'?T_E"@P^#UC*':4=+5&(@+T0:;4@4/!$<9O#<6.DJC6B43@?B,,,QLW
M;_ I2Z??'[P>\CZU@G)&24Y]HM#XED\FA'%3(B'&QY90SB@Y:4@<&NN!U:0(
M'XF$KC_030CVB2F4-DHN&I2'AOM>L92HS9C%]0/(J2T4.$H&&A:(1GQ"UJ/$
M*F,S5DPPUH/W%H'R1TD_07+1PC 2L51+N?>X>2 S^]W<#&02'.)K"D)#@I*7
M/D,Z6F"NDL0BT]L_MTS0;B@ TRAT'&V<(;D8>#.$F9H4K@U9(*(V*9>NSUWGDR^OA0T"#A[/(&B
MT:8(OE+./PBY$F-*M!0T*=*!T"R!MP@T$HASDC5RT<+P1?+,DE+Y E3E^2YX
M3*'8$> ]?=][\7>
MO"#]"FOP&Q40T7M%8KXR)([=0HWB"B\2HCSD0_90]J@;/_U"$>C?F055^_=6
MN4,CF]^%%E34EX)& B6MA8K&N][NO7T@>+D]L(,R1TQ@JX3A[>/*IIS%0RY)
M\+[]P S*%;K9"%AOB:B$>5+4V\N5 ]F0\5#]FD+(,'NF(R$8E'"GOM%IBZV7U>))F&M],Y:I 0
M[*6F@L$F)]/!4"B1*POR]0O5Q.I W2;/I0\0\*:28\P)>R?6F+VJS%^EA78@
M.[ZC(T%('(]-Z1>H>_@J\FTW_1$\L53G058080*MS)HQGC/WB+Q!KRKN@?\\
M0CR>/?$HL;Q PZ9H&66*O&K##-<[2*M4 M:6A 9Z(>VL:(I$21T.BZ:,6G02
M:@^5BX]W:&T"-H(TMMVJ5W68P5 X,>D#M8!(C#8Y3M2QT&)"&$9_KO3KS%B5
MT@';6QZ;U8I[3""A5LTI'F(C6&1=U$0?B@K7DJL$6[)34<]H'G4(+$E(42
M:5Q =G"CRTR)#EU$V1 ,;8ZAW$Z^!F!U/&OI)-BPRGMB;^%1HU%8%^TOA?$
MY2D2CBRO))?FNXJ $9RNN4G$^T53?T2J2N8QB6 [Y!R4AC30YL078.Y@OL
M*#6!(*0(U52!V.ZDDU \D)BSV:Q75(E-[WM@&!*7W_GP_6&]$Z.=&*7,C)4D
M^TA67TI]*](+'14WQD8 :H9$O)K#;/3>WH>,AR7G?-$C(VY?4() F\")S-N
MT^XE(B.X!GU)('9/AT.C\K4D@L 6 1,@'L_!"+7FF%1I4#$-[99;Y*$Z3 -3
MQ&.^^3KU=V+\5_+=3\&*T@C
X2K489!7,Y]U@N)T\0<>W<%Q?(K8QR^"AUA&:4&:6#%1@G@#S0O>(M4(:2%FE0PC/J#'H)X*
MW72SK$3.BA:L=6#T9MG]F!-Z!NW5"2"+"8MT%BZ0X/